Botanix Pharmaceuticals P/E 2024

Botanix Pharmaceuticals Aktienanalyse

What does Botanix Pharmaceuticals do?

Botanix Pharmaceuticals Ltd is an Australian company specializing in the research and development of innovative therapies based on synthetic cannabinoids. The company was founded in 2014 by a team of experts and is headquartered in Perth, Western Australia. The history of Botanix Pharmaceuticals began with the discovery of the medical properties of cannabinoids derived from the hemp plant. Cannabinoids have a wide therapeutic potential, ranging from pain and inflammation relief to the treatment of seizure disorders and anxiety. Botanix Pharmaceuticals utilizes these properties to develop innovative product candidates that have high efficacy and tolerability. The business model of Botanix Pharmaceuticals is based on the concept of targeted treatment for diseases and conditions where traditional therapies are insufficient or cause unwanted side effects. The company develops and produces medications based on synthetic cannabinoids that target specific disease states and indications. Botanix Pharmaceuticals specializes in two areas. Firstly, it focuses on the development of topical products, such as ointments and creams, that are applied to the skin. These products are particularly effective in treating skin conditions such as acne or psoriasis. Secondly, the company is working on the development of medications for the treatment of internal conditions such as epilepsy or chronic obstructive pulmonary disease (COPD). In the field of topical products, Botanix Pharmaceuticals has already achieved significant success. The company has a promising pipeline of product candidates for various applications, including acne, psoriasis, atopic dermatitis, and bacterial infections. One promising drug candidate is BTX 1503, which was developed for the treatment of severe acne. It contains the synthetic cannabinoid BTX 1308, which possesses anti-inflammatory and antimicrobial properties. BTX 1503 has already demonstrated high efficacy and tolerability in clinical studies. In the field of internal conditions, Botanix Pharmaceuticals collaborates closely with leading institutions and research facilities to develop innovative therapies for seizure disorders and COPD. One promising product candidate is BTX 1801, which was developed for the treatment of severe epilepsy. BTX 1801 contains the synthetic cannabinoid BTX 1204, which has shown high efficacy and tolerability in the treatment of seizures. Botanix Pharmaceuticals is an innovative company that develops highly effective and tolerable medications based on synthetic cannabinoids. The company has already achieved remarkable success in a short period and has established itself as a leading player in the industry. With its pipeline of promising product candidates and its close collaboration with renowned research institutions, Botanix Pharmaceuticals is well-positioned to develop further innovative therapies in the future. Botanix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Botanix Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Botanix Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Botanix Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Botanix Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Botanix Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Botanix Pharmaceuticals stock

What is the price-to-earnings ratio of Botanix Pharmaceuticals?

The price-earnings ratio of Botanix Pharmaceuticals is currently -31.4.

How has the price-earnings ratio of Botanix Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Botanix Pharmaceuticals has increased by 203.68% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Botanix Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Botanix Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Botanix Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Botanix Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Botanix Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Botanix Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Botanix Pharmaceuticals?

Some factors that influence the price-earnings ratio of Botanix Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Botanix Pharmaceuticals pay?

Over the past 12 months, Botanix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Botanix Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Botanix Pharmaceuticals?

The current dividend yield of Botanix Pharmaceuticals is .

When does Botanix Pharmaceuticals pay dividends?

Botanix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of April, October, April, November.

How secure is the dividend of Botanix Pharmaceuticals?

Botanix Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Botanix Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Botanix Pharmaceuticals located?

Botanix Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Botanix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Botanix Pharmaceuticals from 10/25/1996 amounting to 0.048 AUD, you needed to have the stock in your portfolio before the ex-date on 10/3/1996.

When did Botanix Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/25/1996.

What was the dividend of Botanix Pharmaceuticals in the year 2023?

In the year 2023, Botanix Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Botanix Pharmaceuticals pay out the dividend?

The dividends of Botanix Pharmaceuticals are distributed in AUD.